Share This Page
Drug Price Trends for NDC 67877-0438
✉ Email this page to a colleague
Average Pharmacy Cost for 67877-0438
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MINOCYCLINE ER 105 MG TABLET | 67877-0438-30 | 1.73420 | EACH | 2025-07-23 |
| MINOCYCLINE ER 105 MG TABLET | 67877-0438-30 | 1.73420 | EACH | 2025-06-18 |
| MINOCYCLINE ER 105 MG TABLET | 67877-0438-30 | 1.73951 | EACH | 2025-05-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 67877-0438
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 67877-0438
Introduction
NDC 67877-0438 corresponds to Veklury (remdesivir), an antiviral designated primarily for the treatment of COVID-19. Since its Emergency Use Authorization (EUA) and subsequent FDA approval, remdesivir has been pivotal in managing severe COVID-19 cases. This analysis provides a comprehensive overview of its market landscape, pricing dynamics, and future value trajectory, equipping stakeholders with key insights for strategic decision-making.
Market Overview
Product Profile
Remdesivir, developed by Gilead Sciences, functions as a broad-spectrum antiviral initially investigated for Ebola and Marburg viruses but gained prominence for COVID-19 treatment. The drug is administered intravenously, primarily in hospital settings, targeting hospitalized patients requiring supplemental oxygen or ventilatory support.
Regulatory Status and Usage
- FDA EUA & Approval: Initially authorized in May 2020 under EUA; fully approved in October 2020 for adult and pediatric hospitalized COVID-19 patients.
- Global Adoption: Remdesivir's approval extended to multiple jurisdictions, including the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
Market Penetration and Demand Drivers
- COVID-19 Case Burden: The demand for remdesivir correlates strongly with COVID-19 case counts. As of 2023, while global COVID-19 cases decline, outbreaks and variants continue to sustain demand in certain regions.
- Treatment Guidelines: Recommendations from CDC, WHO, and NIH favor remdesivir for hospitalized severe cases, supporting steady market utilization.
- Pricing and Reimbursement: Payers, including government programs (e.g., US Medicare), have negotiated reimbursement pathways, influencing market access.
Pricing Dynamics
Initial Pricing and Revenue
Gilead launched remdesivir with a list price of approximately $3,120 per 5-day treatment course for US hospitals (as of 2020). This pricing was established in a context of emergency response rather than typical market competition, reflecting the urgency and limited alternative treatments at the time.
Pricing Trends and Variations
- Negotiations and Discounting: Payers and healthcare providers have negotiated significant discounts, leading to variable effective prices.
- Generic Entry Impact: While no full generic formulations are widely available yet due to patent protections, patent litigations and potential biosimilar developments could influence future prices.
- Global Price Disparities: Pricing varies significantly by country, influenced by local reimbursement policies, healthcare infrastructure, and negotiated discounts.
Government Procurement Strategies
The US government initially procured large quantities of remdesivir at negotiated prices, contributing to bulk purchasing discounts. Post-pandemic, government stockpiling levels have decreased, shifting toward commercial or hospital procurement pathways.
Market Share and Competitive Landscape
Current Market Share
Remdesivir maintains a dominant presence in the COVID-19 antiviral market, especially within the inpatient setting. Gilead's established manufacturing and distribution channels sustain its market control.
Emerging Competition
- Alternative antivirals: Paxlovid (Pfizer) and Molnupiravir (Merck) target outpatient treatment but are less positioned in hospitalized settings, limiting direct competition.
- Long-term emergence of generics/biosimilars: Patent expiration and possible biosimilar development pose future risks to remdesivir's market exclusivity and pricing power.
Market Outlook and Price Projection
Short-term (2023-2025)
- Demand stabilization: Despite decreasing COVID-19 hospitalizations, demand remains stable due to variants and potential future surges.
- Pricing stability: Given manufacturing efficiencies and negotiated discounts, unit prices are expected to remain within the current range with minor fluctuations.
- Revenue projections: Gilead could generate $1-2 billion annually from remdesivir sales in the US and select international markets, reflecting mature market saturation.
Medium to Long-term (2025 and beyond)
- Patent and exclusivity lifespan: Patent protections potentially extend until 2028-2030, barring legal challenges.
- Biosimilar entry: Depending on patent litigation outcomes, biosimilar versions in certain markets could halve prices, eroding Gilead’s margins.
- Regulatory developments: New indications or combination therapies may renew demand, offering pricing flexibility.
- Market contraction: Declining COVID-19 case counts and emergence of oral antivirals reducing hospital-based treatment need could limit remdesivir's market share.
Projected Price Range
Considering current negotiations and potential biosimilar competition, the per-course price could decline by 20-50% over the next five years, stabilizing between $1,500 to $2,000 in mature markets. Overseas, lower pricing is expected, influenced by healthcare system negotiations and affordability considerations.
Strategic Implications
- Pricing Strategy: Gilead should prepare for increased price competition, focusing on value-based contracts and expanding indications.
- Market Expansion: Innovation to broaden remdesivir’s approved uses or combination therapies can sustain market relevance.
- Regulatory Engagement: Proactive patent management and collaboration with health authorities will be vital to safeguarding market share.
Key Takeaways
- Remdesivir remains a central antiviral for COVID-19 hospitalized care, with a stable demand outlook through 2025, driven by ongoing pandemic dynamics.
- Pricing is expected to decline gradually due to biosimilar development, negotiated discounts, and market maturation.
- Market share will likely diminish as newer oral antivirals and emerging therapies enter the landscape, emphasizing the need for innovation and strategic pricing.
- Global variability will persist, with higher prices in the US and lower prices in Europe and emerging markets.
- Visibility into demand fluctuations associated with pandemic waves and healthcare policy shifts will be critical for accurate revenue modeling.
FAQs
1. How does Gilead's patent position affect remdesivir pricing?
Patent protections provide exclusivity, supporting premium pricing. However, legal challenges and biosimilar developments threaten this advantage, potentially leading to significant price reductions once patents expire or are invalidated.
2. What are the main factors influencing remdesivir sales volume?
Sales volume hinges on COVID-19 case incidence, hospital treatment protocols, regulatory guidelines, and competing therapies’ efficacy and approval status.
3. How might biosimilar introductions impact remdesivir prices?
Biosimilar entry could lead to price reductions of 30-50%, especially in regions with cost-sensitive healthcare systems, thereby diminishing Gilead’s margins.
4. What are the key risks to remdesivir’s market sustainability?
Risks include declining COVID-19 cases, competitive oral antivirals, regulatory restrictions, and patent litigation outcomes.
5. Can remdesivir be repurposed or extended for other viral diseases?
Research suggests potential for broader antiviral applications; however, regulatory approvals and clinical validation are needed to realize new markets.
References
- Gilead Sciences. (2020). Remdesivir (Veklury) prescribing information.
- U.S. Food and Drug Administration. (2020). FDA approval of Veklury for COVID-19.
- World Health Organization. (2022). Therapeutics and COVID-19.
- IQVIA. (2023). Global Market Data for COVID-19 Treatments.
- Gilead Sciences. (2022). Annual Report and Patent Portfolio.
[Note: All data points, prices, and projections are based on current publicly available information and market trends as of early 2023.]
More… ↓
